Status:
UNKNOWN
MSC Therapy in Liver Transplantation
Lead Sponsor:
Monia Lorini
Collaborating Sponsors:
Mario Negri Institute for Pharmacological Research
Conditions:
Liver Transplant Rejection
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The general aim of the present study is to test a cell therapy with third-party allogeneic ex-vivo expanded MSCs as a strategy to induce tolerance in liver transplant recipients. MSCs will be prepared...
Eligibility Criteria
Inclusion
- For this study, the following inclusion criteria should be fulfilled before starting withdrawal of drugs after 1 year post-transplant:
- First liver transplant
- Capable of understanding the purpose and risk of the study
- Written informed consent
Exclusion
- Specific contraindication to MSC infusion
- Any clinical relevant condition that might affect study participation and/or study results
- Pregnant women and nursing mothers
- Unwillingness or inability to follow the study protocol in the investigator's opinion.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT02260375
Start Date
October 1 2014
End Date
October 1 2025
Last Update
April 6 2018
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
U.S.C Nefrologia e Dialisi
Bergamo, Italy, 24127
2
USC Chirurgia Generale III
Bergamo, Italy, 24127
3
USC Ematologia
Bergamo, Italy, 24127
4
USC Gastroenterologia
Bergamo, Italy, 24127